The poor prognosis for patients with aggressive or metastatic tumors and the toxic side effects of currently available treatments necessitate the development of more effective tumor-selective therapies. Stem/progenitor cells display inherent tumor-tropic properties that can be exploited for targeted delivery of anticancer genes to invasive and metastatic tumors. Therapeutic genes that have been inserted into stem cells and delivered to tumors with high selectivity include prodrug-activating enzymes (cytosine deaminase, carboxylesterase, thymidine kinase), interleukins (IL-2, IL-4, IL-12, IL-23), interferon-b, apoptosis-promoting genes (tumor necrosis factor-related apoptosis-inducing ligand) and metalloproteinases (PEX). We and others have demonstrated that neural and mesenchymal stem cells can deliver therapeutic genes to elicit a significant antitumor response in animal models of intracranial glioma, medulloblastoma, melanoma brain metastasis, disseminated neuroblastoma and breast cancer lung metastasis. Most studies reported reduction in tumor volume (up to 90%) and increased survival of tumor-bearing animals. Complete cures have also been achieved (90% disease-free survival for 41 year of mice bearing disseminated neuroblastoma tumors). As we learn more about the biology of stem cells and the molecular mechanisms that mediate their tumor-tropism and we identify efficacious gene products for specific tumor types, the clinical utility of cell-based delivery strategies becomes increasingly evident.
Introduction
Stem and progenitor cell-mediated gene delivery is emerging as a strategy to improve the efficacy and minimize the toxicity of current gene therapy approaches. Multiple potential sources for clinically useful stem and progenitor cells have been identified, including autologous and allogeneic embryonic, fetal and adult somatic cells from neural, adipose and mesenchymal tissues. In the case of regenerative medicine, transplanted stem and progenitor cells themselves comprise the therapeutic modality by replacing or regenerating damaged tissue. In the case of enzyme or other genetic deficiencies, these cells may engraft and express the deficient enzyme or gene product. A third potential use for stem and/or progenitor cells, and the topic of this review, is their use as delivery vehicles for therapeutic gene products. Current evidence indicates that systemically administered stem/progenitor cells migrate to and infiltrate primary and metastatic solid tumors, and that these cells can be used to deliver therapeutic genes, cDNAs or siRNAs selectively to tumor foci. We and others envision that this inherent tumor-tropism of stem/progenitor cells can be exploited to develop effective, well-tolerated treatments for patients with malignant solid tumors.
Neural and mesenchymal stem/progenitor cells, isolated from various tissue sources, possess a remarkable inherent tumor tropism. The major advantage in using stem/progenitor cells as delivery vehicles lies in their potential to achieve a heretofore unachievable therapeutic specificity. Neural stem/progenitor cells, and mesenchymal stem cells (MSCs) harvested from bone marrow or adipose tissue, for example, display tumortropic properties in preclinical models of malignant primary and metastatic tumors. This tropism has been exploited to deliver multiple therapeutic genes or cDNAs selectively to tumor foci (summarized in Table 1 ; stem and progenitor cells for tumor-selective therapy). 3, 10, [15] [16] [17] [23] [24] [25] [26] [27] [28] [29] [30] [31] The central question to be addressed then becomes whether we can exploit the inherent ability of these cells to migrate to, infiltrate and-when desirable-engraft to 'correct' pathologies in patients. The long-range goal is complete cure without toxic side effects or relapse. The principal criteria that will determine the clinical utility of these strategies are safety, feasibility and efficacy. This review will focus on the advantages of neural stem/ progenitor cells as delivery vehicles for tumor-selective therapy in models of primary and metastatic cancer. We will discuss the sources of stem and progenitor cells available, the types of 'therapeutics' that might be delivered, approaches to engineering the cells to express these genes and factors that will increase the likelihood that cell-based delivery systems will be clinically useful.
Tumor tropism and infiltrative potential
Based on their unique tropism to sites of pathology, the principal advantage of stem/progenitor cell-based delivery of anticancer therapeutics is in the potential to increase the tumor-specificity and therefore the therapeutic index of therapies of interest. Importantly, and in striking contrast to virtually all other delivery approaches, neural stem/progenitor cells migrate to and infiltrate bulk tumors in vivo, and target invasive tumor cells ( Figure 1 ). This ability to localize to and distribute through tumor masses would be predicted to mediate a more complete and robust antitumor response than vehicles with more restricted distribution potential such as modified liposomes, 32-34 conjugated antibodies, tumor or organ-specific expression cassettes, nanoparticles or polymers, [35] [36] [37] or modified viruses of various genotypes (reviewed in Waehler et al.
38
). While each approach undoubtedly has advantages and disadvantages, cell-based approaches compare favorably with all approaches currently being investigated. Targeted liposomes, antibodies or modified viruses rely on interaction of proteins or peptides with 'receptors' on the surface of targeted tumors or organs. The presumption that must be made with these types of targeted approaches is that proteins (or other surface molecules) can be identified, which are sufficiently unique in level or pattern of expression to serve as 'specific receptors' for the targeting moiety. In antitumor approaches, for example, numerous constructs have been reported that target transferrin receptor, [39] [40] [41] [42] [43] [44] [45] since this receptor has been reported to be expressed at levels approximately twofold higher in tumors than in normal tissues. 46, 47 Intuitively, a twofold difference may not provide a sufficient differential between tumor and normal tissue to confer tumor selectivity, unless the dose-response curve of the therapeutic entity is very steep.
The tumor-tropism of cell-based delivery is likely mediated by multiple cell-surface and secreted proteins, and does not depend exclusively on the expression of a single protein or 'receptor'. While the molecular basis for the tumor-tropism of stem/progenitor cells in vivo is poorly understood, it has been observed that numerous cytokines, growth factors and receptors modulate migration in vitro. Candidate cytokine/receptor pairs include SDF-1/CXCR4, 48 SCF/c-Kit, 49, 50 HGF/c-Met, 51 VEGF/VEGFR, 52 MCP-1/CCR2 53 and HMGB1/RAGE. 54, 55 Among adhesion molecules, b1-and b2-integrins, and L-selectin may play a significant role in the mobilization and homing of stem cells. [56] [57] [58] Extracellular matrix proteins, and MMP2, MT1-MMP and TIMP-2 have also been associated with the tropism of stem/progenitor cells. 59, 60 However, the molecular mechanisms of stem/ progenitor migration to tumors of various origins and phenotypes have yet to be elucidated. Table 1 Continued Cell-mediated anticancer therapy KS Aboody et al
Stem and progenitor cell survival in vivo
A second advantage to cell-based delivery is that cells can be manipulated to survive long-or short term in vivo. Clearly, individual applications will determine which alternative is more appropriate. Correction of a genetic enzyme deficiency using bone marrow MSCs or neural stem/progenitor cells engineered to express a functional human enzyme would require long-term delivery cell survival-either resulting from engraftment or from fusion with endogenous cells. For chemotherapy applications, delivery cells need to survive only sufficiently long to mediate effective therapy. This type of approach is exemplified by cell-based delivery of prodrug-activating enzymes such as Herpes simplex virus thymidine kinase, to activate (phosphorylate) ganciclovir, Escherichia coli cytosine deaminase (CD) to convert 5-fluorocytosine (5-FC) to 5-fluorouracil, or carboxylesterase (CE) to convert CPT-11 (irinotecan) to SN-38. 20, [61] [62] [63] [64] [65] [66] [67] [68] We have found that in the absence of anticancer drug treatment, neural stem/progenitor cells remain viable, at least 2-3 weeks following intratumoral injection into mice bearing orthotopic gliomas. Similarly, other laboratories have noted stem cell survival of 2-12 weeks in preclinical models of cerebral ischemia/stroke, Parkinson's disease and Huntington's disease. [69] [70] [71] [72] [73] Interestingly, in the latter type of pathological environments, neural stem/progenitor cells have been reported to differentiate into neurons and/or glial cells over time. In contrast, in mice that have received drug treatment as a component of stem cell/enzyme/prodrug tumor therapy for neuroblastoma, we found no evidence of long-term stem cell survival 16 and unpublished observations). Of note, neural stem/progenitor cells injected into the brain of normal immunocompetent or immunocompromised mice begin to undergo apoptosis within 72 h (KS Aboody et al., unpublished data). There is some evidence that a subpopulation of stem or progenitor cells fuse with endogenous cells, [74] [75] [76] but our studies with immortalized neural stem/progenitor cell lines have not corroborated this finding. Fusion may be characteristic of the particular stem/progenitor cells or cell line used. It has also been reported that MSCs engraft into the stroma of tumors, resulting in persistence of the clonal population of exogenous stem cells. 19, 26, 77, 78 The critical concern for all approaches will be the careful design of vectors and characterization of the specific stem/progenitor cells, to ensure that their duration of survival is appropriate to the specific clinical application of interest. A Phase 1 neural stem cell (NSC)-mediated glioma therapy clinical trial is currently under development (Aboody and Portnow, City of Hope National Medical Center). This trial includes biologic studies to determine the characteristics of NSC persistence, fate and distribution in the human brain.
Tissues targeted by cell-based delivery vehicles and cellular localization of delivered transgenes
A third advantage of stem/progenitor cells compared to other types of delivery vehicles, is the ability of these cells to migrate to tumor foci regardless of tumor size, anatomic location or tissue of origin. 30 When administered intracranially or intravenously, cloned NSC lines, for example, migrate to orthotopic gliomas, 3, 8 medulloblastoma 10, 14 and melanoma brain metastases 10 in preclinical models. The unique characteristic of efficiently crossing the blood-brain barrier provides a very attractive advantage in treating central nervous system (CNS)-associated tumors. Intravenously administered NSCs also migrate to disseminated neuroblastoma tumors in multiple anatomic locations, including the liver, ovaries and bone marrow. 15, 16 NSCs also migrate to subcutaneous xenografts in mice bearing tumors from human breast, prostate and melanoma tumor cell lines. 10, 21, 26, 30, 79 These observations suggest that the potential for clinical application of cell-mediated delivery of therapeutic transgenes may be quite extensive. For each therapeutic application, however, it will also be important to be cognizant of molecular processing required, once cellmediated delivery of a therapeutic has reached the target site. An antibody-drug conjugate, for example, would be endocytosed into cells and sequestered within endosomes in the cytoplasm. A curative amount of active Cell-mediated anticancer therapy KS Aboody et al drug must then traffic from the endosome to the intracellular organelle that is sensitive to the cytotoxic effect of the drug. In comparison, cells as delivery vehicles may not be subject to endosomal compartmentalization, but other characteristics must be considered, such as how efficiently the prodrugs or activated forms of these drugs cross cell membranes and how the permeability characteristics of each form of the drug might affect overall antitumor efficacy. Details of specific components of individual therapeutic approaches notwithstanding, the general abilities of stem and progenitor cells to traverse the blood brain barrier and to migrate to multiple types and sizes of tumors in various anatomical locations are obvious advantages of cellbased delivery vehicles.
Availability of stem and progenitor cells
As we become more proficient at harvesting and expanding appropriate stem and progenitor cells in vitro or at de-differentiating abundant somatic cells, [80] [81] [82] [83] cell number will become less of an issue. Methods are also being developed to harvest stem cells from organs other than those commonly used thus far. In addition to bone marrow, umbilical cord, adipose tissue and brain, recent reports indicate that dental pulp, 84 first trimester fetal blood 85 or embryonic endothelial cells 86 may also be sources of therapeutically useful stem or progenitor cells. Currently, however, while standard methods are available to produce virtually unlimited quantities of antibodies, viruses, liposomes or PEGylated nanoparticles, culture methods have not yet been perfected to rapidly produce unlimited quantities of undifferentiated stem and progenitor cells. The lack of adequate numbers of autologous cells, or the limited amount of time available to expand, modify and test them is currently a limitation of patient-derived cell-based delivery vehicles. Furthermore, these pools of primary expanded cell cultures may change over time during passage, thereby making them extremely difficult to characterize or to establish master cell banks. We believe that this constraint is efficiently overcome by use of immortalized, clonal stem/progenitor cell lines. Following selection and clonal expansion, cell lines can be tested for stability, biodistribution, safety and toxicity. Well-characterized cell lines may then be expanded into master cell banks for clinical use.
Immortalized, clonal stem/progenitor cell lines
Well-characterized cell lines of allogeneic origin have been used in preclinical models of glioma, medulloblastoma, melanoma, neuroblastoma and breast carcinoma (Table 1) with some noteworthy successes. The use of well-characterized, immortalized allogeneic cell lines for clinical trials would circumvent problems of cell availability and minimize potential insertion site-mediated toxicities (discussed below), but will make it necessary to evaluate the tumorigenic and immunogenic potentials of the cells themselves and of the vector used to engineer transgene expression. Readily available autologous stem cell sources would be ideal. Potential tissue sources for these cells have been suggested, with cells from each source having unique properties. For example, Kern et al. 87 observed that MSCs from bone marrow had a lower proliferation capacity in vitro than MSCs from umbilical cord blood or adipose tissue, making stem cells from the latter two sources attractive alternatives to the thus far more frequently used bone marrow MSCs based on the consideration of cell number. However, the likelihood that adequate numbers of autologous cells will be available or can be generated by culturing for a limited time in vitro is unknown and may depend on the cell type being used. Further, even if adequate numbers of pathology-free autologous cells could be generated, the time required to genetically modify, expand, characterize and certify these cells might prohibit their use in patients with a limited life expectancy. The high cost and limited number of centers capable of producing such cells might well also be prohibitive. We propose that well-characterized, cloned cell lines comprise clinically useful delivery vehicles.
Cell lines as delivery vehicles: toxicity or the lack thereof-tumorigenicity and immunogenicity
Toxicity/tumorigenicity
Preclinical data and results of early, cell-based gene therapy patient trials suggest that the most likely toxicity of cell-based gene therapies is the generation of secondary malignancies. 88 Allogeneic cell lines used as delivery vehicles could be predicted to be tumorigenic by three mechanisms: (1) expression of the gene used to immortalize the delivery cell line transforms the cells; (2) insertion of the immortalizing or therapeutic transgene at a critical locus in the genome dysregulates expression of other proteins and induce tumors and (3) the delivery cell fuses with endogenous cells, and the resulting fused cell has a transformed phenotype.
With respect to the first mechanism, several genes have been evaluated for their potential utility in immortalizing stem cells for use as delivery vehicles: the proto-oncogene v-myc, 3, 70, 72, [89] [90] [91] the catalytic component of the telomerase complex (human telomerase reverse transcriptase (hTERT)), human papillomavirus type 16 E6/E7 genes, Bmi-1 [92] [93] [94] [95] [96] [97] [98] [99] and an N-terminal fragment of SV40 large T-antigen. 2, 100 Characteristics of the resultant cell lines, each of which had extended life spans in culture, have been reviewed. 101 Pertinent to the focus of the current review, several cell lines immortalized with hTERT and SV40 large T fragment were observed to be unstable with respect to chromosome number and karyotype. Additional evidence suggests that ectopic expression of telomerase in MSCs increases their resistance to radiation, 102 whereas in NT2 neural progenitors, hTERT inhibits neuronal differentiation. 103 In contrast, the cell lines with which our laboratories have the most experience were immortalized using the vmyc gene. 70, 72 The multiple antitumor studies performed with murine (C17.2) or human (HB1.F3) clonal populations of v-myc-immortalized fetal neural cells are indicated in Table 1 and have been reviewed previously. 30 These cells do not form colonies in soft agar (MK Danks, unpublished observations) and have not been observed to form tumors in SCID mice up to 12 With respect to the second potential mechanism of tumorigenesis, the critical nature of the genomic insertion site of genes used to immortalize cell lines or as components of therapy is well documented by a recent clinical trial. In this trial, patients with immune deficiencies received uncloned autologous hematopoietic stem cells that had been transduced with retrovirus. In a subset of patients, leukemogenic clonal populations of cells survived. As reviewed recently by Pike-Overzet et al., 88 the engrafted populations of hematopoietic cells that survived had incorporated the exogenous nucleotide sequence at sites adjacent to loci encoding LMO2, LYL1, c-Jun, Bmi1 or CCND2. Insertions at these sites upregulated expression of genes, which, when highly expressed, transformed T cells. The critical concern becomes, in any given cell type, if an exogenous gene or cDNA inserts into the host cell genome, is the expression of any 'nearby' gene altered and is upregulation of that gene likely to impact on the phenotype of the type of cell into which the gene was inserted? (It should be noted that cell lines immortalized using retroviruses to insert hTERT, SV40 large T, Bmi-1 and E6/E7 have not been extensively characterized. Since insertion sites were not mapped, hTERT itself may not be tumorigenic, but its insertion may have disrupted another critical genomic locus and transformed the delivery cell. Before telomerase-immortalized cell lines are used clinically, it will be essential to determine which of these alternatives is responsible for any observed tumor development.) In leukocytes, unfortunately, there is documentation from clinical trials that insertion of an exogenous gene near at least five specific genetic loci increases the tumorigenic potential. Based on these data, one would postulate that if cells of neuronal, rather than hematopoietic, origin were used as delivery vehicles it would be important to determine that insertion of exogenous sequences near genetic loci encoding MYC-N or EGFR, for example, did not alter expression of these genes. Pike-Overzet et al. 88 suggest that detrimental insertion sites likely differ in different cell types. The difficulty in characterizing all insertion sites in uncloned populations of primary transduced cells again emphasizes a potential advantage of cloned characterized cell lines compared to primary cells as vehicles, if therapeutic transgenes have been incorporated into the delivery cell genome.
With respect to the third mechanism noted above, delivery cells could potentially become tumorigenic through fusion of the delivery cell with a tumor cell. This is least likely of the three potential mechanisms for multiple reasons. First, hyperdiploid cells have not been observed in animals receiving stem/progenitor cells. Second, Foroni et al. 104 showed that expression of exogenous c-myc immortalizes primary stem cells, but does not transform them. Importantly, these investigators also showed that co-expression of myc and ras did not transform adult NSCs. Third, embryonic stem cells appear to have a greater capacity for fusion than fetal or adult cells, 105, 106 and the HB1.F3 cells are of fetal origin. Further, multiple studies found no evidence of bone marrow MSCs or NSC fusion with hepatocytes, pancreatic endocrine cells, endothelial cells or epidermis. [107] [108] [109] [110] While high levels of specific cytokines can induce fusion of MSCs with cardiomyocytes or striated muscle cells, 111, 112 it appears that nonembryonic stem cells have little capacity to fuse with cells of a recipient organism. Possibly, fetal or adult stem or progenitor cells will have more utility than embryonic stem cells as delivery vehicles.
Immunogenicity
Primary neural stem and progenitor cells have been characterized by multiple laboratories as having low, if any, immunogenic potential in their undifferentiated state. Hori et al. 113 reported that CNS progenitor cells do not express MHC class I or II antigens either at the time of harvest, upon culture in 10% serum or when grown as subcapsular renal grafts in vivo. Interestingly, in vitro culturing of primary adipose-derived cells for 3-4 passages diminished their ability to stimulate proliferation of allogeneic responder T-cells to below detectable levels. While a minimal-to-no immunogenic potential is certainly possible since, for example, the HB1.F3 cell line used in our laboratories expresses undetectable levels of MHC Class I antigens and extremely low levels of Class II antigens, the more likely probability is that reported by Aboody et al. 3 These investigators showed that stem/ progenitor cells of neural origin elicit a subacute, limited, local immune response characterized by detectable T-cell infiltration, but with persistence of viable HB1.F3 human NSCs in syngeneic models of immunocompetent mice bearing syngeneic orthotopic gliomas. Should it become necessary in a clinical setting to suppress immune responses to allogeneic cell lines, we note that in a murine model of metastatic neuroblastoma, the immunosuppressive agent cyclosporin did not affect the tumor-tropic properties of the HB1.F3 cells (MK Danks et al. unpublished observations). Whether the immunogenicity of cells from allogeneic sources will limit their utility will ultimately need to be evaluated in clinical trials, but multiple types of data indicate that the immunogenicity of at least some of these cell lines is not prohibitive. Consideration must also be given to the potential immunogenicity of the therapeutic gene or vector used to introduce this gene into the delivery cell line. In particular, there are clearly instances in which genes from non-human sources provide a greater therapeutic benefit. If the immunogenic potential of the vector or the transgene prohibits clinical use, obvious alternative are to use 'empty vectors', to delete immunogenic sequences not required for protein function, or to 'humanize' immunogenic domains of non-human coding sequences, as has been reported for the rabbit CE that efficiently activates the prodrug irinotecan. 114 Until conditions are identified that permit unlimited expansion of clonal populations of autologous primary cells engineered to express a therapeutic of interest, wellcharacterized cell lines are most likely to have clinical utility.
Methods/vectors for engineering cells to express therapeutic transgenes
Stem and progenitor cells used as delivery vehicles must be engineered to express the therapeutic of interest. Most 119 has been reported. While a discussion of the advantages and disadvantages of each type of virus is beyond the scope of this review, major differences among these vectors include whether or not they integrate into the genome of the recipient cell, their ability to transduce the intended delivery cells, their immunogenic potential, and the level of transgene expression that can be expected from each. If long-term transgene expression is necessary, a vector that integrates into DNA such as retrovirus would be preferable; but then, as discussed above with respect to constructs used to generate immortalized cell lines as delivery vehicles, clonal populations of transduced cells must be isolated, expanded and the DNA integration sites mapped. Similarly, transfection methods could be used to introduce genes of interest into delivery cells, but this approach may also necessitate cloning and mapping of genomic integration sites. In contrast, adenoviral vectors can be used to mediate transient, high-level transgene expression without integration into the host cell genome, but then the immunogenic potential of intracellular adenovirus particles would need to be carefully evaluated. Circumvention or minimization of vector 'issues' will vary with each approach. Potentially, depending on the context of treatment, patients may already be immune deficient or the site of pathology might be in an immune-privileged site, thereby minimizing the potential for induction of an immune response.
Choice of therapeutic transgene
Stem and progenitor cells can be engineered to express various antitumor gene products, and deliver these products selectively to tumor foci. Gene products that have been evaluated thus far include prodrug-activating enzymes, inducers of apoptosis, differentiating agents, cell cycle modulators, anti-angiogenesis factors, immune-enhancing agents and oncolytic factors (Table 1) . Cellular vehicles may also serve as virus producer cells, allowing more protracted and selective delivery of oncolytic viruses. 120 Different types of therapeutics will likely be best delivered by different types of cells that have been engineered specifically to target a given disease. For most anticancer applications, it seems reasonable transient high-level expression of therapeutic entities would produce the most robust and durable responses. Appropriate (effective) vector design and 'therapeutic entities' will depend heavily on the tumor targeted. While an extensive review of transgenes is beyond the scope of this commentary, a representative list of genes and tumor types that have been investigated is found in Table 1 . In each case, the preclinical outcome likely depended on the level and duration of expression of the therapeutic gene at tumor foci, the dosing schedule of cell-mediated and -associated treatments, the appropriateness of the molecular target, and the ability of the therapeutic entities to interact with and modify the function of that target.
Therapeutic efficacy of tumor-selective cell-mediated gene delivery in preclinical models

General considerations
The majority of studies thus far have used MSCs or NSCs engineered to express an enzyme that activates a nontoxic prodrug. The hypothesis evaluated by this approach is based on the expression of the prodrugactivating enzyme preferentially at tumor foci, and the production of high concentrations of active drug at tumor sites. A specific example of this approach is shown in Figure 2 , however, similar approaches using neural stem/progenitor cells to deliver various therapeutic genes have been used for other solid tumors, including glioma, medulloblastoma, melanoma, breast and prostate cancer (Table 1) .
It is envisioned that this type of approach will improve therapeutic efficacy without additional toxicity. Essential to the anticipated improvement in therapeutic index is not only an increase of active drug at tumor foci, but also demonstration that the plasma concentration of active drug or therapeutic transgene does not increase compared to treatment with prodrug alone. Two recent publications examined these parameters. The first evaluated levels of enzyme and activated prodrug in systemic circulation of mice treated with HB1.F3 cells expressing a CE that efficiently converts the prodrug CPT-11 to SN-38. 16 Plasma levels of CE activity and SN-38 were comparable in mice receiving HB1.F3 cells transduced with adenovirus to express CE and CPT-11 compared to CPT-11 alone. The second study quantitated plasma levels of interferon-b in mice treated with HB1.F3 cells expressing this cytokine. Circulating levels of IFN-b were undetectable in mice receiving 2 million HB1.F3 cells Cell-mediated anticancer therapy KS Aboody et al transduced with adenovirus to express IFN-b. 17 These results suggest that little 'leakage' away from tumor foci occurs and that the probability is good that tumorselective therapy can be achieved using this approach (Figure 3 ).
Specific considerations
For additional information regarding specific genes, we refer the reader to recent reviews that focus on prodrugactivating enzymes used in gene therapy. 67, 121, 122 In the brief discussions that follow, our intent is to highlight notable specific or unique features of research design or preclinical therapeutic outcomes in published studies focused on individual therapeutic transgenes. 123 Using this approach, we have observed 470-80% decrease in tumor volume of mice bearing orthotopic invasive gliomas or intracranial melanoma, compared to the tumor volume in untreated mice or mice receiving NSCs or prodrug only. 3, 10 The CD/5-FC strategy also merits evaluation in eradicating or preventing liver metastases of colon adenocarcinoma, since 5-FU is front-line for the treatment of this tumor type.
Carboxylesterase
Another enzyme/prodrug combination that shows promise in preclinical studies is that of rabbit CE/CPT-11 (irinotecan). 15, 16, 124, 125 Studies from our laboratory using this combination employed HB1.F3 cells transduced with adenovirus to express a rabbit CE (rCE; EC.3.1.1.1) that efficiently converts CPT-11 to SN-38, a potent topoisomerase I inhibitor. Expression of rCE is regulated by the CMV promoter. Intravenous administration of HB1.F3.rCE cells and CPT-11 produced long-term survival (greater than one year) in 90% of mice bearing multiple disseminated (metastatic) neuroblastoma. To our knowledge, this is the most durable and complete response published thus far using cell-mediated delivery approaches. The durable response may be attributable to the optimized 'matching' of the cells, vector, enzyme, prodrug and schedules of administration of each component with the targeted tumor type. Adenovirus produced extremely high levels of rCE expression. rCE activates CPT-11 more efficiently than human enzymes. CPT-11 has shown encouraging, albeit not curative, activity in neuroblastoma patients. Efficacious schedules of administration of CPT-11 for the treatment of neuroblastoma are known. 126 Each component of the 'system' was targeted specifically to try to attain complete remissions without recurrence specifically for disseminated neuroblastoma tumors. 16 As is the case for CD/5FC, the combination of CE/CPT-11 also merits evaluation for potential efficacy in the treatment of colon adenocarcinoma, since CPT-11 is one of the most effective agents for the treatment of this tumor type.
Other enzyme/prodrug combinations
The two enzyme/prodrug combinations discussed above represent a small portion of combinations that have been reported in the literature; and the reader is referred to the previously mentioned excellent reviews for additional information on this topic. However, we propose that the efficacy of the activated prodrug in treating human tumors should be a primary consideration of which prodrugs are investigated in gene therapy enzyme/ prodrug studies in the future. If, clinically, antitumor efficacy of a given activated prodrug has relatively limited activity in the treatment of human tumors, then time, intellectual and financial resources would be better spent designing and characterizing novel combinations rather than conducting additional proof of principle experiments with available combinations simply because they are available.
Interleukins
Using a different therapeutic approach, SV40 large T antigen-immortalized primary mouse NSCs transduced with retrovirus to express interleukin 4 (IL-4) have been evaluated for efficacy in treating C6 rat gliomas or syngeneic GL261 mouse gliomas.
2 IL-4 enhances T-cellmediated immune responses to tumor cells. 127 Treatment of IL-4-expressing NSCs produced a 90-day survival of 480% of mice when tumor cells were co-injected with IL-4-secreting NSCs, compared to 0% 30-day survival in untreated mice. When a similar approach was used to Cell-mediated anticancer therapy KS Aboody et al treat established GL261 tumors, 71% of mice survived for 90 days, whereas only 33% of tumor-bearing mice that received control NSCs were alive at this timepoint. 2 In a similar study, immortalized Sprague-Dawley embryonic rat NSCs transduced with retrovirus to express IL-4 were implanted into C6 gliomas, which resulted in prolonged survival of the treated rats, when compared to untreated controls. 2 In other studies, treatment of GL261 tumorbearing rats with NSC-IL-12 cells significantly prolonged survival and produced long-term antitumor immunity compared to animals treated with unmodified NSCs. 4, 128 Bone marrow-derived neural stem-like cells (BMNSCs) have also been used to express and deliver another interleukin: interleukin-23 (IL-23). Administration of these BM-NSC-IL-23 cells inhibited tumor growth rate in C57BL/6 mice bearing gliomas.
9 CD8+ T-cells were essential for producing the observed antitumor effects mediated by IL-23-expressing BM-NSCs. Importantly, the IL-23-expressing BM-NSC-treated mice that survived were resistant to tumor re-challenge. These data show that IL-23-expressing BM-NSCs induce immune-mediated antitumor effects in preclinical models of intracranial glioma.
Tumor necrosis factor-related apoptosis-inducing ligand (APO-2L)
NSCs transduced with an adenoviral vector encoding human tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) have also shown efficacy in rodent models of intracranial glioma. 5 These modified NSCs produced an increase in apoptotic cells in these tumors, and were associated with a significant inhibition in the rate of tumor progression. Importantly, Shah et al. 7 designed a secreted version of TRAIL (S-TRAIL) to improve access of the therapeutic gene product to its molecular target, a cell membrane surface protein on cells adjacent to the NSCs. Intracranially implanted NSCs expressing S-TRAIL migrated into the gliomas and effected a 480% reduction in tumor growth. Since TRAIL induces apoptosis in tumor cells, [129] [130] [131] but has relatively few effects on most normal cells, 132 TRAIL is attractive as potentially useful in gene therapy approaches to treatment.
PEX
Another type of protein product that has been evaluated for efficacy in treating intracranial gliomas is the human metalloproteinase-2 fragment PEX. PEX inhibits glioma and endothelial cell proliferation and migration, and angiogenesis. 133, 134 The antitumor activity of human HB1.F3 cells expressing PEX was investigated in mice bearing malignant gliomas. Intratumoral injections of these modified NSCs reduced tumor volume by 90%, 8 and this reduction was concomitant with a decrease in angiogenesis and cell proliferation. Given the critical role of metalloproteinases in tumor invasion and progression, additional approaches to inhibit MMP function or, perhaps, to design prodrugs that are activated by MMPs, need to be investigated further.
Interferon-b
A fourth type of cell-mediated approach to the treatment of solid tumors has been reported by Dickson et al. 17 These investigators used HB1.F3 cells to deliver interferon-b to tumor foci, with the intent of normalizing tumor vasculature prior to administration of cytotoxic agents. 135 The expectation was that by improving the functional status of tumor vasculature, chemotherapeutic agents given subsequently would penetrate the tumor mass more extensively and a significant increase in their antitumor efficacy would be observed. HB1.F3 cells expressing interferon-b, when given alone, had little antitumor effect in mice bearing orthotopic neuroblastoma tumors; but these cells significantly enhanced the antitumor effect of cyclophosphamide, a chemotherapeutic agent used in the treatment of neuroblastoma. Studies are currently underway to evaluate the ability of HB1.F3.IFN-b cells to sensitize tumors to other chemotherapeutic agents such as CPT-11 or doxorubicin that are relatively efficacious in the treatment of this tumor type. This general approach, with appropriate choice of chemotherapeutic agent, could be applicable to the treatment of other solid tumors as well.
Summary and future directions
The poor prognosis for patients with metastatic and invasive tumors and the toxic side effects of currently available treatments necessitate the development of effective tumor-selective therapies. Current data suggest that the inherent tumor-tropic properties of stem/ progenitor cells can be exploited to develop safe effective targeted therapy for these cancers. Several candidate genes/gene products have been mentioned in this commentary. However, more importantly, emerging safety and efficacy data for cell-mediated delivery will hopefully stimulate new efforts to identify novel genes for the treatment of specific tumor types. Further, studies to elucidate chemotactic factors and signaling pathways that regulate the tumor-tropism of stem and progenitor cells will facilitate identification of tumor types that would best respond to cell-mediated gene delivery. In vivo human safety and efficacy data critical to the success of the described approach include: cell distribution and duration of survival, with and without administration of conventional chemotherapy; identification of 'safe' genomic insertion sites for exogenous genes; confirmation of the predicted minimal immunogenic potential of stem/progenitor and cells; and minimization of the immunogenicity of non-human gene products. Further, and a theme throughout this commentary, it is likely that the type of delivery cell, the therapeutic gene and the vector used to engineer gene expression must be tailored to specific tumor types, if the optimal therapeutic benefit is to be realized. We also propose that, at least initially, cell-mediated approaches to cancer therapy will have the greatest impact in eradicating minimum residual disease in patients that have achieved apparent complete or near-complete remission with conventional therapy, but whose prognostic factors indicate that relapse with metastatic disease is highly likely.
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